Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerBusiness Wire · 21 hr ago
AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 EarningsSeeking Alpha · 1 day ago
FDA Conditionally Approves AstraZeneca's Rare Kidney Disease DrugBenzinga · 2 days ago
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyZacks Investment Research · 2 days ago
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsBusiness Wire · 2 days ago
AstraZeneca says FDA approves drug for rare kidney disease in adultsReuters · 3 days agoAstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 27, 2026 | $2.50 | $2.63 | Beat |
| Apr 29, 2026 | $2.57 | $2.58 | Beat |
| Feb 10, 2026 | $2.09 | $2.12 | Beat |
| Nov 6, 2025 | $2.28 | $2.38 | Beat |
| Jul 29, 2025 | $2.18 | $2.18 | Beat |
| Apr 29, 2025 | $2.20 | $2.48 | Beat |